Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that its Medi-Span® solution has been expanded to include a new Patient Safety Programs File™. The application enables health IT systems to rapidly identify drugs containing specific characteristics that require surveillance based on federal regulations.
Along with its ability to help facilitate compliance with government reporting requirements, the Patient Safety Programs File also supports development of patient safety initiatives by incorporating drug indicators into the workflows of clinician end-users. The application identifies drugs that require a Risk Evaluation and Mitigation Strategies (REMS) program and includes a summary of the REMS programs. This summary can be incorporated directly into the clinician’s workflow to provide the type of information they need for the program when at the point of care. The file can also include the associated Medication Guides as reported by the manufacturer in PDF and PCL5 formats. Other supported indicators include:
Black Box Warnings (BBW) including text of warning in XML format
Medication Guide requirements outside of REMS
Acetaminophen Ingredient
Pseudoephedrine Ingredient
Tall Man Drug Names
“The regulatory landscape unfolding within the healthcare industry leaves no room for error when it comes to medications and adverse drug events,” said David Del Toro, Vice President and General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “By adding the Patient Safety Programs File to our Medi-Span drug database offerings, we are equipping healthcare organizations with the automation needed to help r
